Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
18 Outubro 2023 - 8:00AM
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage
biopharmaceutical company developing novel immunotherapies for the
treatment of cancer, today announced that it will present four
posters at the Society for Immunotherapy of Cancer (SITC) 38th
Annual Meeting. The conference is being held at the San Diego
Convention Center in San Diego, Calif. and virtually from November
1-5, 2023.
“We are using our best-in-class ISAC platform and expertise in
myeloid biology to teach the immune system to work with each
patient’s body to recognize and kill cancer,” said Michael Alonso,
PhD, scientific co-founder and Vice President, Immunology &
Pharmacology of Bolt Biotherapeutics. “Our research team has made
significant progress across our portfolio, highlighting our
commitment to generate breakthroughs for patients. In addition to
clinical-stage data that further validate our Boltbody™ ISAC
technology, we are excited to show at SITC for the first time our
preclinical work with a trastuzumab ISAC and pertuzumab and how the
combination augments anti-tumor efficacy in multiple HER2+ tumor
models relative to trastuzumab plus pertuzumab.”
Details about the poster presentations can be found below and on
the SITC website. Additionally, a copy of each poster will be
available on the Publications page of the Bolt
Biotherapeutics website at the start of the poster session.
Title: The combination of a trastuzumab ISAC
and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor
models relative to trastuzumab plus
pertuzumabPresenter: Cecelia I. Pearson,
Ph.D.Session Date and Time: Friday November 3,
2023, 9:00 a.m. – 7:00 p.m. PSTLocation: San Diego
Convention Center, Poster Hall Abstract Number:
821
Title: Preclinical Characterization of a Novel
Claudin 18.2 Targeting-ISAC with Robust Potency and Acceptable
Safety ProfilePresenter: Han Kim,
Ph.D.Session Date and Time: Friday November 3,
2023, 9:00 a.m. – 7:00 p.m. PSTLocation: San Diego
Convention Center, Poster Hall Abstract Number:
1147-D
Title: Phase 2 study of the HER2-targeting
TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001
monotherapy +/- nivolumab in patients with HER2+ colorectal,
endometrial, or gastroesophageal cancerPresenter:
Ecaterina Dumbrava, M.D. Session Date and Time:
Saturday November 4, 2023, 9:00 a.m. – 8:30 p.m.
PSTLocation: San Diego Convention Center, Poster
Hall Abstract Number: 716
Title: A Phase 1/2 study of BDC-3042, a novel
Dectin-2 agonistic antibody, in patients with advanced
cancersPresenter: Antonio Giordano, M.D., Ph.D.
Session Date and Time: Saturday November 4, 2023,
9:00 a.m. – 8:30 p.m. PSTLocation: San Diego
Convention Center, Poster Hall Abstract Number:
720
About the Boltbody™ Immune-Stimulating Antibody
Conjugate (ISAC) Platform Bolt Biotherapeutics’ Boltbody
ISAC platform harnesses the precision of antibodies with the power
of the innate and adaptive immune system to reprogram the tumor
microenvironment to generate a durable anti-cancer response. Each
Boltbody ISAC candidate comprises a tumor-targeting antibody, a
non-cleavable linker and a proprietary immune stimulant. The
antibody is designed to target one or more markers on the surface
of a tumor cell, and the immune stimulant is designed to recruit
and activate myeloid cells. Activated myeloid cells initiate a
positive feedback loop by releasing cytokines and chemokines,
chemical signals that attract other immune cells and lower the
activation threshold for an immune response. This increases the
population of activated immune system cells in the tumor
microenvironment and promotes a robust immune response with the
goal of generating durable therapeutic responses for patients with
cancer.
About Bolt Biotherapeutics, Inc. Bolt
Biotherapeutics is a clinical-stage biopharmaceutical company
leveraging the immune system for a better way to treat cancer. The
company is developing novel immunotherapies using an approach that
teaches the immune system to recognize and kill cancer in a way
that is immediately personalized to each patient. Its pipeline
candidates are built on the Company’s deep expertise in myeloid
biology and cancer drug development and include BDC-1001, a
HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate
(ISAC) being evaluated in a Phase 2 trial, and BDC-3042, a
myeloid-modulating agonist antibody targeting Dectin-2, being
evaluated in a Phase 1 trial. Bolt Biotherapeutics is also
developing multiple Boltbody™ ISACs in strategic collaborations
with leading biopharmaceutical companies. For more information,
please visit https://www.boltbio.com/.
Forward-Looking Statements This press release
contains forward-looking statements about us and our industry that
involve substantial risks and uncertainties and are based on our
beliefs and assumptions and on information currently available to
us. All statements other than statements of historical facts
contained in this press release, including statements regarding the
clinical value of combining BDC-1001 with pertuzumab, the safety
and anti-tumor activity of our Claudin 18.2 ISAC, and the timing of
the completion of our clinical trials, are forward-looking
statements. In some cases, you can identify forward-looking
statements because they contain words such as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on
track,” “plan,” “potential,” “predict,” “project,” “should,”
“will,” or “would,” or the negative of these words or other similar
terms or expressions. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our
actual results, performance, or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements represent our current beliefs, estimates
and assumptions only as of the date of this press release and
information contained in this press release should not be relied
upon as representing our estimates as of any subsequent date. These
statements, and related risks, uncertainties, factors and
assumptions, include, but are not limited to: the potential product
candidates that we develop may not progress through clinical
development or receive required regulatory approvals within
expected timelines or at all; clinical trials may not confirm any
safety, potency or other product characteristics described or
assumed in this press release; such product candidates may not be
beneficial to patients or become commercialized; and our ability to
maintain our current collaborations and establish further
collaborations. These risks are not exhaustive. Except as required
by law, we assume no obligation to update these forward-looking
statements, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future. Further information on factors that could cause actual
results to differ materially from the results anticipated by our
forward-looking statements is included in the reports we have filed
or will file with the Securities and Exchange Commission, including
our Annual Report on Form 10-K for the year ended December 31,
2022. These filings, when available, are available on the investor
relations section of our website at investors.boltbio.com and on
the SEC’s website at www.sec.gov.
Investor Relations and Media Contact:Maeve
ConneightonArgot Partners(212)
600-1902boltbio@argotpartners.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024